Statement: The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients.
Primary_evidence: Adverse Events 1:   Total: 9/2788 (0.32%)   Anaphylaxis 5/2788 (0.18%)   Infections and infestations - Other, specify 2/2788 (0.07%)   Nervous system disorders - Other, specify 0/2788 (0.00%)   Respiratory, thoracic and mediastinal disorders - Other, specify 1/2788 (0.04%)   Thromboembolic event 1/2788 (0.04%) Adverse Events 2:   Total: 8/2800 (0.29%)   Anaphylaxis 5/2800 (0.18%)   Infections and infestations - Other, specify 0/2800 (0.00%)   Nervous system disorders - Other, specify 1/2800 (0.04%)   Respiratory, thoracic and mediastinal disorders - Other, specify 1/2800 (0.04%)   Thromboembolic event 2/2800 (0.07%)